Education
About Us
Working with TipRanks
Follow Us
Immunic, Inc. (IMUX)
:IMUX
IMUX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.88 - $2.11
Previous CloseN/A
Volume261.21K
Average Volume (3M)665.38K
Market Cap
$85.03M
Enterprise Value$108.93M
Total Cash (Recent Filing)$38.19M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta2.01
Next Earnings
May 08, 2025EPS Estimate
-0.23Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.03
Shares Outstanding90,150,870
10 Day Avg. Volume799,507
30 Day Avg. Volume665,380
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-1.20
P/FCF Ratio0.00
Enterprise Value/Market Cap1.28
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-981.33
Enterprise Value/Ebitda-1.14
Forecast
1Y Price Target
$10.04Price Target Upside1015.56% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
---
Bulls Say, Bears Say
Bulls Say
Market PositionThe recent setback of a competitor therapy in RMS positions vidofludimus calcium as a potential disruptor in the oral RMS therapy market.
Therapeutic PotentialVidofludimus calcium is differentiated by its oral, dual mode-of-action as a prospective disease modifying therapy, targeting the full spectrum of MS disease with neuroprotection and relapse prevention.
Bears Say
Clinical RiskThe readout is not without clinical risk, given the reliance on Nurr1 activation for potential efficacy.
Financial UncertaintyThe financing outlook post-CALLIPER readout remains a key outstanding question, making clarity on the funding status important for the stock reaction.
---
Ownership Overview
9.12% Insiders
5.52% Mutual Funds
40.21% Other Institutional Investors
40.67% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
IMUX FAQ
What was Immunic, Inc.’s price range in the past 12 months?
Immunic, Inc. lowest stock price was $0.88 and its highest was $2.11 in the past 12 months.
What is Immunic, Inc.’s market cap?
Immunic, Inc.’s market cap is $85.03M.
When is Immunic, Inc.’s upcoming earnings report date?
Immunic, Inc.’s upcoming earnings report date is May 08, 2025 which is in 29 days.
How were Immunic, Inc.’s earnings last quarter?
Currently, no data Available
Is Immunic, Inc. overvalued?
According to Wall Street analysts Immunic, Inc.’s price is currently Undervalued.
Does Immunic, Inc. pay dividends?
Immunic, Inc. does not currently pay dividends.
What is Immunic, Inc.’s EPS estimate?
Immunic, Inc.’s EPS estimate is -0.23.
How many shares outstanding does Immunic, Inc. have?
Immunic, Inc. has 90,150,870 shares outstanding.
What happened to Immunic, Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Immunic, Inc.?
Currently, no hedge funds are holding shares in IMUX
---
Immunic Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$10.04 (1015.56% Upside)
$10.04 (1015.56% Upside)
Blogger Sentiment
Bullish
IMUX Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 118.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $99.5K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 1.8%
Last 30 Days ▼ 1.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-30.62%
12-Months-Change
Fundamentals
Return on Equity
-424.44%
Trailing 12-Months
Asset Growth
-24.74%
Trailing 12-Months
Company Description
Immunic, Inc.
Immunic, Inc. (IMUX) is a clinical-stage biopharmaceutical company focused on developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases. The company's lead product candidate, IMU-838, is an orally available, selective immune modulator that targets diseases such as multiple sclerosis and inflammatory bowel disease. Immunic leverages its proprietary technology platforms to advance its pipeline of innovative therapies.
---
IMUX Stock 12 Month Forecast
Average Price Target
$10.04
▲(1015.56% Upside)
Technical Analysis
Arrowhead Pharmaceuticals
―
BioCryst
―
Cytokinetics
―
RedHill Biopharma
―
Viking Therapeutics
―
Best Analysts Covering IMUX
1 Year
1 Year Success Rate
1/13 ratings generated profit
1 Year Average Return
-34.42%
reiterated a buy rating 21 days ago
Copying Yasmeen Rahimi's trades and holding each position for 1 Year would result in 7.69% of your transactions generating a profit, with an average return of -34.42% per trade.
---